Deal Intelligence Platform & Services for Global M&A / PE
Oct 3 (Reuters) – Shares of LogicBio Therapeutics (LOGC.O) skyrocketed on Monday after Britain’s AstraZeneca’s (AZN.L) said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.
Source
Author: unknown
Bain Capital is exploring a partial exit from Bridge Data Centres (BDC), a Singapore-headquartered hyperscale operator, in a deal that could value the platform at more than $4 billion. The private...
In a move that signals a fundamental restructuring of global sports governance, FIFA has moved to carve out its commercial operations into a new, for-profit entity valued at $20 billion. The...
PARIS/LISBON — In a move that intensifies the consolidation of European skies, Air France-KLM on Wednesday submitted a binding offer for a significant minority stake in TAP Air Portugal. The bid,...
TL;DR Swiss industrial giant ABB is signaling a shift to multi-billion dollar acquisitions, funded by the $5.4 billion divestiture of its robotics division to SoftBank. Chairman Peter Voser...